Advertisement

Pulmonary Surfactant: Evolution of Functional Concepts

  • G. Enhorning
Conference paper
  • 62 Downloads

Abstract

The first and clear indication that surface tension offers resistance to the initial lung aeration after birth came with von Neergaard’s study in 1929 [26]. He found that lungs that were collapsed would open up more readily if the effect of surface tension was completely nullified by using liquid rather than air as the expanding medium. Following this basic study, it took considerable time until Pattle in 1955 [19] could declare that he assumed there was an agent present in the lung that had the ability to depress surface tension to extremely low values. He extruded bubbles from the sectioned lung and found that when they were surrounded by saline, so that they could be studied under a microscope, they would quickly shrink 30% from their initial size, when their diameter was around 40 µ, but then the bubbles would persist for long periods of time (Fig. 1). Pattle reasoned that the high surface tension of water, 72 mN/m, ought to give an enormously high pressure in the tiny bubble, so that the gas inside the bubble should have been absorbed quickly by the surrounding saline solution. When this did not happen, but the bubble persisted, Pattle concluded that there must be a lining layer exerting surface pressure, almost completely counteracting the collapsing effect of water surface tension. The net surface tension according to Pattle must be very close to 0.

Keywords

Surface Tension Adult Respiratory Distress Syndrome Pulmonary Surfactant Large Airway Hyaline Membrane Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Adams FH, Fujiwara T, Emmanouilides G, Scudder A (1965) Surface properties and lipids from lungs of infants with hyaline membrane disease. J Pediatr 66: 357–364PubMedCrossRefGoogle Scholar
  2. 2.
    Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97: 517Google Scholar
  3. 3.
    Chu J, Clements JA, Cotton EK, Klaus MH, Sweet AY, Tooley WH (1967) Neonatal pulmonary ischemia. I Clin Physiol Studies 40: 709–766Google Scholar
  4. 4.
    Clements JA (1957) Surface tension of lung extracts. Proc Soc Exp Biol Med 95: 170–172PubMedGoogle Scholar
  5. 5.
    Clements JA (1961) Pulmonary edema and permeability of alveolar membranes. Arch Environ Health 2: 280PubMedGoogle Scholar
  6. 6.
    Enhorning G (1977) Photography of peripheral pulmonary airway expansion affected by surfactant. J Appl Physiol 42: 976–979PubMedGoogle Scholar
  7. 7.
    Enhorning G (1977) Pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol 43: 198–203PubMedGoogle Scholar
  8. 8.
    Enhorning G, Robertson B, Milne E, Wagner R (1972) Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 50: 58–66PubMedGoogle Scholar
  9. 9.
    Enhorning G, Robertson B, Milne E, Wagner R (1975) Radiologic evaluation of the premature newborn rabbit after pharyngeal deposition of surfactant. Am J Obstet Gynecol 121: 475–480PubMedGoogle Scholar
  10. 10.
    Enhorning G, Hill F, Sherwood G, Cutz E, Robertson B, Bryan C (1978) Improved ventilation of prematurely delivered primates following tracheal deposition of surfactant. Am J Obstet Gynecol 132: 529–536PubMedGoogle Scholar
  11. 11.
    Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J (1985) Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics 76: 145–153PubMedGoogle Scholar
  12. 12.
    Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T (1980) Artificial surfactant therapy in hyaline membrane disease. Lancet 1: 55–59PubMedCrossRefGoogle Scholar
  13. 13.
    Gitlin JD, Soll RF, Parad RN, Horbar JD, Feldman HA, Lucey JF, Taeusch HW (1987) Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics 79: 31–37PubMedGoogle Scholar
  14. 14.
    Hallman M, Merritt A, Jarvenpaa AL, Boynton B, Mannino F, Gluck L, Moore T, Edwards D (1985) Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 106: 963–969PubMedCrossRefGoogle Scholar
  15. 15.
    Kwong MS, Egan EA, Notter RH, Shapiro DL (1985) Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics 76: 585–592PubMedGoogle Scholar
  16. 16.
    Merritt TA, Hallman M, Bloom BT, Berry C, Benirschke K, Sahn D, Key T, Edwards D, Jarvenpaa AL, Phojavouri M, Kankaanpaa K, Kunnas M, Paatero H, Rapola J, Jaaskelainen J (1986) Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 315: 785–790PubMedCrossRefGoogle Scholar
  17. 17.
    Metcalfe IL, Pototschnik R, Burgoyne R, Enhorning G (1982) Lung expansion and survival in rabbit neonates treated with surfactant extract. J Appl Physiol 53: 838–843PubMedGoogle Scholar
  18. 18.
    Morley CJ, Bangham AD, Miller N, Davis JA (1981) Dry artificial lung surfactant and its effect on very premature babies. Lancet 1: 64–68PubMedCrossRefGoogle Scholar
  19. 19.
    Pattle RE (1955) Properties, function and origin of the alveolar lining layer. Nature 175: 1125–1126PubMedCrossRefGoogle Scholar
  20. 20.
    Pattle RE (1958) Properties, function, and origin of the alveolar lining layer. Proc R Soc Lond [Biol] 148: 217–240CrossRefGoogle Scholar
  21. 21.
    Raju TNK, Bhat R, McCullough KM, Maeta H, Vidasagar D, Sobel D, Anderson M, Levy PS, Furrier S (1987) Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease. Lancet 1: 651–656PubMedCrossRefGoogle Scholar
  22. 22.
    Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A (1964) Microaerosol administration of synthetic ß-y-dipahnitoyl–L-a-lecithin in the respiratory distress syndrome: a preliminary report. Can Med Assoc J 90: 55–57PubMedGoogle Scholar
  23. 23.
    Ruler R (1967) Der Einfluß oberflächenaktiver Substanzen auf Entfaltung and Retraktion isolierter Lungen. Pflügers Arch 298: 170–184CrossRefGoogle Scholar
  24. 24.
    Shannon DC, Kazemi H, Merril EW, Smith KA, Wong PSL (1969) Restoration of volume-pressure curves with a lecithin fog. J Appl Physiol 28: 470–473Google Scholar
  25. 25.
    Shapiro DL, Notter RH, Morin FC, Deluga KS, Golub LM, Sinkin RA, Weiss M, Cox C (1985) Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76: 593–599PubMedGoogle Scholar
  26. 26.
    von Neergaard K (1929) Neue Auffassungen über einen Grundbegriff der Atemmechanik. Z Ges Exp Med 66: 373–394CrossRefGoogle Scholar
  27. 27.
    Wallin A, Burgoyne R, Enhorning G (1977) Oxygen consumption of the newborn rabbit treated with pulmonary surfactant. Biol Neonate 31: 245–251PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • G. Enhorning

There are no affiliations available

Personalised recommendations